Drugs / Allogeneic Prostate GVAX®
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00140400 | May 1999 → Jan 2001 | prostate cancer | Cell Genesys | Completed | No outcome recorded |
| Phase 1/2 | NCT00140387 | May 1999 → Mar 2001 | prostate cancer | Cell Genesys | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Prostate GVAX | “The objective of this study is to evaluate the safety and efficacy of priming vaccinations, and subsequent boosting vaccinations with Human GM-CSF Gene Transduced Irradiated...” NCT00140387 ↗1“Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®)” NCT00140400 ↗ |
| Modality | Vaccine | “Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines” NCT00140387 ↗ |